H. P. Acthar gel, or repository corticotropin (rACTH), was approved by the US Food and Drug Administration (FDA) in 1952 and currently is indicated for the treatment of infantile spasms, exacerbations of multiple sclerosis, and, nebulously, “rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state.”1 The unremarkable history of this little-known drug is in contrast to its astounding rise in price, detailed in this issue of JAMA Internal Medicine, by Hartung and colleagues.2 The authors found that the price of the drug to Medicare increased almost overnight from $1650 to over $24 000 per 5-mL vial when it was acquired by Questcor in 2001 and continued to rise. It was acquired by Mallinckrodt in 2014, who increased the price yet again. It is currently $34 034 per 5 mL vial. Remarkably, Medicare spent $1.3 billion dollars on Acthar gel between 2011 and 2015.2
Shakil S, Redberg RF. New (Very High) Prices on Old Drugs. JAMA Intern Med. 2017;177(11):1568. doi:10.1001/jamainternmed.2017.3775
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: